These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 17923609

  • 1. I can't get no satisfaction: still no neuroprotection for Parkinson disease.
    Ahlskog JE.
    Neurology; 2007 Oct 09; 69(15):1476-7. PubMed ID: 17923609
    [No Abstract] [Full Text] [Related]

  • 2. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
    Wang LH, Johnson EM.
    Neurology; 2008 Aug 05; 71(6):462; author reply 462-3. PubMed ID: 18678833
    [No Abstract] [Full Text] [Related]

  • 3. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
    Parkinson Study Group PRECEPT InvestigatorsDepartment of Neurology, University of Rochester Medical Center, 1351 Mt Hope Ave, Ste 218, Rochester, NY 14620, USA..
    Neurology; 2007 Oct 09; 69(15):1480-90. PubMed ID: 17881719
    [Abstract] [Full Text] [Related]

  • 4. D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways.
    Chen S, Zhang X, Yang D, Du Y, Li L, Li X, Ming M, Le W.
    FEBS Lett; 2008 Mar 05; 582(5):603-10. PubMed ID: 18242171
    [Abstract] [Full Text] [Related]

  • 5. Disease-modifying drugs and Parkinson's disease.
    Allain H, Bentué-Ferrer D, Akwa Y.
    Prog Neurobiol; 2008 Jan 05; 84(1):25-39. PubMed ID: 18037225
    [Abstract] [Full Text] [Related]

  • 6. CEP-1347 (Cephalon).
    Mucke HA.
    IDrugs; 2003 Apr 05; 6(4):377-83. PubMed ID: 12789610
    [No Abstract] [Full Text] [Related]

  • 7. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
    Schwarzschild MA.
    Neurology; 2010 Nov 23; 75(21):1943-4; author reply 1944-5. PubMed ID: 21098412
    [No Abstract] [Full Text] [Related]

  • 8. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
    Montgomery EB.
    Neurology; 2010 Nov 23; 75(21):1943; author reply 1944-5. PubMed ID: 21155188
    [No Abstract] [Full Text] [Related]

  • 9. Why hasn't neuroprotection worked in Parkinson's disease?
    Kieburtz K, Ravina B.
    Nat Clin Pract Neurol; 2007 May 23; 3(5):240-1. PubMed ID: 17479072
    [No Abstract] [Full Text] [Related]

  • 10. Erythropoietin as a neuroprotective agent in traumatic brain injury Review.
    Mammis A, McIntosh TK, Maniker AH.
    Surg Neurol; 2009 May 23; 71(5):527-31; discussion 531. PubMed ID: 18789503
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil.
    Takada-Takatori Y, Kume T, Ohgi Y, Izumi Y, Niidome T, Fujii T, Sugimoto H, Akaike A.
    J Neurosci Res; 2008 Dec 23; 86(16):3575-83. PubMed ID: 18655200
    [Abstract] [Full Text] [Related]

  • 12. Okadaic acid protects human neuroblastoma SH-SY5Y cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis.
    Ahn KH, Kim YS, Kim SY, Huh Y, Park C, Jeong JW.
    Neurosci Lett; 2009 Jan 09; 449(2):93-7. PubMed ID: 19000740
    [Abstract] [Full Text] [Related]

  • 13. Future neuroprotective strategies.
    Sättler MB, Bähr M.
    Exp Neurol; 2010 Sep 09; 225(1):40-7. PubMed ID: 19716365
    [Abstract] [Full Text] [Related]

  • 14. Neuroprotection in spinal cord injury.
    Wyndaele JJ.
    Spinal Cord; 2009 Oct 09; 47(10):715. PubMed ID: 19794416
    [No Abstract] [Full Text] [Related]

  • 15. Lost in translation: again, another failed neuroprotection trial.
    Brew BJ.
    Neurology; 2007 Sep 25; 69(13):1308-9. PubMed ID: 17893290
    [No Abstract] [Full Text] [Related]

  • 16. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
    Naoi M, Maruyama W.
    Expert Rev Neurother; 2009 Aug 25; 9(8):1233-50. PubMed ID: 19673610
    [Abstract] [Full Text] [Related]

  • 17. Prolonged morphine application modulates Bax and Hsp70 levels in primary rat neurons.
    Chen Q, Cui J, Zhang Y, Yu LC.
    Neurosci Lett; 2008 Aug 29; 441(3):311-4. PubMed ID: 18601975
    [Abstract] [Full Text] [Related]

  • 18. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases.
    Saporito MS, Hudkins RL, Maroney AC.
    Prog Med Chem; 2002 Aug 29; 40():23-62. PubMed ID: 12516522
    [Abstract] [Full Text] [Related]

  • 19. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
    Verma R, Nehru B.
    Neurochem Int; 2009 Nov 29; 55(6):369-75. PubMed ID: 19375462
    [Abstract] [Full Text] [Related]

  • 20. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW, Kieburtz K, Schapira AH.
    Ann Neurol; 2008 Dec 29; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.